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Calcium oxalate kidney stones are a common condition aﬀecting many people in the United States. The concentration of oxalate
in urine is a major risk factor for stone formation. There is evidence that glyoxal metabolism may be an important contributor
to urinary oxalate excretion. Endogenous sources of glyoxal include the catabolism of carbohydrates, proteins, and fats. Here, we
review all the known sources of glyoxal as well as its relationship to oxalate synthesis and crystal formation.
1.Introduction
Endogenous oxalate synthesis makes an important contribu-
tion to the amount of oxalate excreted in urine and hence
the development of calcium oxalate kidney stones, a painful
condition that aﬄicts 10% of the adult Caucasian male pop-
ulation in the United States. The biochemical pathways
involvedinoxalateproductionarepoorlyunderstooddespite
decades of research. However, it is clear that glyoxylate is the
major precursor of oxalate [1]. The metabolism of a number
of substances has been proposed as a source of glyoxylate
including glycine, phenylalanine, tryptophan, hydroxypro-
line, glucose, fructose, pentose sugars, ethanolamine, and
glycolate. Our research to date indicates that of these poten-
tialsources,hydroxyprolinemakesamodestcontribution,5–
10%, and the majority of others provide negligible amounts
[2–4]. We have found, however, by incubating a variety of 2
carbon molecules with hepatocytes, that glyoxal is a promi-
nent source of glyoxylate [3]. We hypothesize that glyoxal is
one of the most important sources of endogenous oxalate
synthesis in humans and possibly other organisms and is one
that has been overlooked to date. Mounting evidence is also
suggestingthatbothglyoxalproductionandoxalatesynthesis
can be associated with oxidative stress.
2.Glyoxal
Glyoxal (O=CH–CH=O) is an α-oxoaldehyde, and it is often
grouped with two similar α-oxoaldehydes, methylglyoxal,
and 3-deoxyglucosone. All three compounds are products of
various metabolic and oxidative reactions and are capable of
causing cellular damage and apoptosis [5]. They are also in-
volved in the formation of advanced glycation end-products
(AGEs) which have been linked to long-term sequela of
chronic diseases such as diabetic retinopathy, neuropathy,
and nephropathy [6]. Glyoxal is primarily detoxiﬁed by the
glyoxalase system present in the cells of bacteria, protozoa,
fungi, plants, animals, and humans [7]. However, it has been
suggested that several other enzymes are capable of detox-
ifying glyoxal, including aldehyde dehydrogenase (ALDH)
which can oxidize glyoxal to glyoxylate [5, 6].
3.Sourcesof Glyoxal
Glyoxal originates from both exogenous and endogenous
pathways.Exogenous sources are primarily dietary, and these
include beer, wine, tea, coﬀee, yogurt, bread, rice, soybean
paste, soy sauce, and oil [8]. Foods that have been fermented,
roasted,baked,orfriedarealsoarichsourceofglyoxal.Envi-
ronmental sources of glyoxal include cigarette smoke, smoke
from residential log ﬁres, vehicle exhaust, smog, fog, and
somehouseholdcleaningproducts.Itmayalsobeintroduced
into the air during combustion of various materials. It has
been found in samples of soil, groundwater, seawater, and
sediment. Whether glyoxal from these sources is absorbed
into the body through the gut, lungs, or skin to signiﬁcantly
aﬀect glyoxal levels in tissues is not known with certainty.2 Advances in Urology
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Figure 1: Sources of glyoxal.
In addition to the many exogenous sources of glyoxal, it
is endogenously produced via autoxidation of carbohydrates
and ascorbate, degradation of glycated proteins and lipid
peroxidation [9]. Glyoxal can be formed through various
pathways as illustrated in Figure 1. It is created directly from
glucose via retroaldol condensation, and it is formed in-
directly from glucose via a glycoaldehyde intermediate that
undergoes autoxidation. The autoxidation reaction is pro-
moted by the presence of phosphate buﬀer and trace metal
ions (Fe3+ and Cu2+) in solution. The latter was indirectly
demonstrated by a reduction of glycoaldehyde autoxidation
by the presence of the trace metal ion chelator diethylenetri-
aminepentaacetic acid [10].
Anotherwayinwhichglucosecanbeconvertedtoglyoxal
is via a Schiﬀ base intermediate [10]. A Schiﬀ base is a func-
tional group that contains a carbon-nitrogen double bond
and is formed from the acyclic form of glucose reversibly
reacting with an amino acid (typically lysine or arginine)
[11]. Once the Schiﬀ base forms, it exists primarily in the
cyclic form, but it can exist in an acyclic form that revers-
ibly rearranges through an Amadori rearrangement to an
Amadori product. The Amadori product can either be oxi-
dized by a metal catalyst to form an AGE or undergo autox-
idation and produce glyoxal [10]. It is through this mech-
anism that AGEs and fructosamine, an Amadori product,
contribute to glyoxal production [6, 10].
Manini et al. have demonstrated that glyoxal cannot only
be formed from glucose but from many other carbohydrates
as well,including galactose,mannose, fructose,ribose, arabi-
nose,ribulose,glyceraldehyde,acetone,adenosine,mannitol,
andglycerol[12].Themechanismbywhichglyoxalisformed
from carbohydrates, including identiﬁcation of intermedi-
ates, has been extensively studied by Hofmann et al. [13].
Ascorbate will also spontaneously hydrolyze into glyoxal via
an unknown mechanism [14].
Although sugars are often regarded as the main source,
lipid peroxidation is also a potentially important source of
glyoxal. Three general steps occur during autoxidation of
lipid molecules: initiation, propagation, and termination. In
this case, initiation occurs when polyunsaturated fatty acids
such as linoleic and linolenic acid undergo nonenzymatic
lipid peroxidation. The resultant product is a hydroperoxide
which then degrades into a variety of oxidation products,
including glyoxal [15]. Spiteller et al. have suggested that
such aldehydes are formed by a second dioxygenation of the
primary hydroperoxides formed [16]. Glyoxal has been
identiﬁed among the autooxidation products of linoleic and
linolenic acids [17, 18] and has been detected in ischemic
porcine heart tissue [19]. Clearly, the formation of glyoxal
associated with the peroxidation that occurs in a number of
disease states warrants further investigation.
4.Metabolism
The bulk of the glyoxal formed in tissues is converted to
glycolate by the glyoxalase system (consisting of glyoxalase I
and glyoxalase II) located in the cytosol of all cells [5].
Glyoxalase I also exists in the endoplasmic reticulum of cells,
while glyoxalase II can additionally be found in the mito-
chondria. The activity of glyoxalase I is greatest in human
pancreas,lung,kidney,andbraintissueandlowestinadipose
and liver tissue. Interestingly, the glyoxalase I activity of fetalAdvances in Urology 3
tissues is three times higher than in adult tissues [7]. It is also
possible that glyoxal could be converted to glycolate by free
radical initiated reactions, but such a nonenzymatic pathway
has not yet been identiﬁed in biological systems.
Glyoxal conversion to glycolate requires glutathione
(GSH). In situations where GSH is depleted, as might occur
with oxidative stress, other enzymes such as aldehyde reduc-
tase,aldosereductase,carbonylreductase,aldehydedehydro-
genase, and 2-oxoaldehyde dehydrogenase may be involved
in the metabolism of glyoxal [5, 6, 20] .T h ep r e s e n c eo f
sorbinil, an aldose reductase inhibitor, has been found to
inhibit metabolism of glyoxal, leading to high intracellular
concentrations and eventual cell death [6]. Elevated intra-
cellular glyoxal levels may inhibit aldehyde reductase, glu-
tathione reductase, and NADPH-producing enzymes. In
addition, high glyoxal concentrations produce reactive oxy-
gen species (ROS) and formaldehyde, they increase cell sus-
ceptibility to hydrogen peroxide, and they disrupt the mito-
chondrial membrane potential, further showcasing its toxic
eﬀects [6, 21].
Certain substances have been found to increase the rate
of glyoxal metabolism and are thus cytoprotective. These
include antioxidants (e.g., butylated hydroxyanisole), iron
chelators (e.g., desferoxamine), and NADH generators (e.g.,
xylitol and sorbitol) [6, 21] .T h ed e c r e a s ei nc y t o t o x i c i t yi n
the presence of the antioxidant reinforces the hypothesis that
ROSproducedfromlipidperoxidationmaycontributetothe
toxic eﬀects of glyoxal [6]. In addition, Shangari et al. found
that the extent of cellular damage caused by glyoxal accumu-
lation in hepatocytes could be decreased by the use of glyoxal
“traps,” including d-penicillamine, aminoguanidine, argi-
nine, cysteine, and pyridoximine. They also prevented GSH
depletion and lipid peroxidation from occurring. Thiamine
deﬁciency also increases hepatocytes susceptibility to gly-
oxal toxicity [21]. These studies demonstrate that glyoxal
metabolismanditstoxicityarecomplex,andfurtherresearch
is required to resolve the mechanisms involved.
5. Relationship betweenGlyoxaland Oxalate
There is both inferential and direct evidence that glyoxal
is involved in endogenous oxalate synthesis. Inferential evi-
dence is provided by studies of diabetics. They have higher
plasma glyoxal levels than controls (perhaps due to increased
lipid peroxidation and protein glycation) as well as increased
urinary oxalate excretion [22–24]. Diabetics also have a
higher risk of stone formation [25]. Direct evidence was ob-
tained in studies with HepG2 cells, a hepatoma-derived cell
line. When they were incubated with glyoxal, oxalate was
generated [3]. Incubation of liver homogenates with glyoxal
further revealed that glyoxal can be converted to glyoxylate,
the major precursor of oxalate, by an NAD+-dependent reac-
tion (Figure 2). The inhibition of the reaction by disulﬁram
suggests that the reaction is being catalyzed by an aldehyde
dehydrogenase. The possible metabolism associated with the
conversion of glyoxal to oxalate is depicted in Figure 3.
This proposed pathway for oxalate generation has several
repercussions for identifying the pathways that contribute
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Figure 2: Conversion of glyoxal to glyoxylate in liver tissue homo-
genates. Incubations contained 0.2mM glyoxal, 50mM TRIS pH
9.0,100mMKCl,1mMEDTA,1mghumanliverlysate,10minutes,
37◦C. Reaction additions: 1mM NAD+,1 m MN A D P +,1 m M
disulﬁram. Glyoxylate was measured in perchloric acid extracts by
reversed phase HPLC after derivatization with 10mM phenylhy-
drazine.
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Figure 3: Potential mechanisms for oxalate synthesis from glyoxal.
Enzymes involved include (1) glyoxylase I, (2) glyoxylase II, (3)
aldehyde dehydrogenase, (4)glycolate oxidase, (5)glyoxylate reduc-
tase, (6) lactate dehydrogenase, (7) D-amino acid oxidase, and (8)
alanine:glyoxylate aminotransferase.
to endogenous oxalate synthesis and developing strategies to
modify calcium oxalate stone formation. Sources of glyoxal
should be identiﬁed, steps involved in the conversion of
glyoxal to oxalate determined, the role of oxidative stress and
inﬂammation studied, and the role of antioxidant therapies
in decreasing oxalate synthesis examined. Furthermore, the
contribution of individual tissues to whole body oxalate
productioninvariousmetabolicstateswarrantsclariﬁcation.
An important question is whether an increased endogenous
o x a l a t es y n t h e s i si sa ni n d e xo fw h o l eb o d yp e r o x i d a t i o n .
Such analyses will, however, require a careful separation of
the oxalate derived from this source and that derived from
the diet. As an increased glycolate synthesis should occur in
association with glyoxal formation, urinary glycolate excre-
tion may give a “cleaner” view of whole body peroxidation.
Inthisregard,ithasbeenpreviouslynotedthat,insomeidio-
pathic calcium oxalate stone formers, there is an apparent
association between elevated excretions of both oxalate and
glycolate [26, 27].4 Advances in Urology
6. CalciumOxalateinTissues
The accumulation of calcium oxalate deposits in tissues is
known as oxalosis. Oxalosis can occur via both hereditary
(i.e., primary hyperoxalurias) and other mechanisms. The
accumulation of small amounts of calcium oxalate crystals in
the absence of aberrant oxalate metabolism has been termed
dystrophic oxalosis [28] .T h i sh a sb e e nr e p o rt e di nan u m b e r
of tissues including arterial atherosclerotic plaques, myo-
cardium, lymph nodes, testis, thyroid, breast, ocular tissues,
andkidneyswithacquiredcysticdisease[28,29].Inthestudy
of calciumoxalate deposits in coronary artery atherosclerotic
plaques, the 4 patients all had chronic diseases that can
increase oxidative stress levels, including AIDS, hepatitis C,
sepsis, ischemic heart disease, and cancer [28]. Calcium
oxalate crystals were also found in myocardium, lymph
nodes, testis, and thyroid tissues [28]. Oxalate crystals have
frequently been observed in thyroid and breast tissue and
are typically linked to benign disease more than malignant
[30, 31]. Calcium oxalate deposition in the retina has been
reported after trauma and in the lens of glaucoma patients
[32]. A common theme of many of these disorders is oxida-
tive stress which we believe promotes the generation of more
glyoxal and its metabolism to oxalate. This may promote the
oxalate deposition described in the aforementioned tissues.
This may be impacted by the duration of oxidative stress. For
example, end-stage renal disease is associated with oxidative
stress. Enoki et al. reported that oxalate deposition in the
kidneysofpatientswithacquiredcysticdiseasewaspositively
correlated with the number of months being on dialysis [29].
Calcium oxalate crystals appear to arise at focal points in
most tissues. The underlying changes in oxalate metabolism
andthefactorsassociatedwiththiscrystalformationwarrant
further research.
7. Summary
We have presented evidence that glyoxal is an important
substrate for endogenous oxalate synthesis and as a result
may be a critical factor in calcium oxalate urolithiasis. Exo-
genous sources of glyoxal, such as the diet and the atmo-
sphere,mostlikelymakeonlyaminorcontribution.Endoge-
nous sources may be more important and derived from the
catabolism of carbohydrates, proteins, and fats through var-
ious metabolic reactions, some of which are not yet fully
understood. Oxidative stress likely plays a crucial role in
glyoxal formation through the interplay between the lipid
peroxidation pathway and the autoxidation of sugars and
glycated proteins. Calcium oxalate crystal deposition has
been noted in tissues under conditions of increased oxidative
stress. There is still a great need for further study to identify
the associations between glyoxal formation and oxalate syn-
thesisaswellastodecipherwaystomodifytheseinteractions.
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